SCHEMBL12989063

SCHEMBL12989063

CC(C)CCCC(C)C1CCC2C3CC=C4CC(OC(=O)CCOCCOCCOCCOCCNC(=O)OC(C)(C)C)CCC4(C)C3CCC12C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.60
▸ CYP46A1 Q9Y6A2 2/20 0.59
▸ PLA2G2A P14555 1/20 0.56
▸ USP2 O75604 2/20 0.55
▸ OSBP P22059 2/20 0.55
▸ RORC P51449 2/20 0.55
▸ OSBP2 Q969R2 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ ABCB1 P08183 1/20 0.55
▸ NR1H3 Q13133 4/20 0.53
▸ NPC1L1 Q9UHC9 5/20 0.53
▸ NPC1 O15118 1/20 0.51
▸ GBA1 P04062 2/20 0.51
▸ UGCG Q16739 2/20 0.51
▸ GBA2 Q9HCG7 2/20 0.51
▸ CRYAB P02511 1/20 0.49
▸ HMGCR P04035 1/20 0.49
▸ ITGB3 P05106 1/20 0.49
▸ ITGAV P06756 1/20 0.49
▸ SREBF2 Q12772 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15007261 1.00 POLA1 (0.60) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL3514954 1.00 POLA1 (0.60) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL3514956 1.00 POLA1 (0.60) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL16509091 0.95 POLA1 (0.62) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL26032472 0.95 POLA1 (0.63) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL15702072 0.95 POLA1 (0.63) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL17665326 0.95 POLA1 (0.63) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL26032430 0.94 POLA1 (0.64) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL25835344 0.94 POLA1 (0.64) POLA1CYP46A1PLA2G2AUSP2OSBP
SCHEMBL26041071 0.92 POLA1 (0.60) POLA1CYP46A1PLA2G2AUSP2OSBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205283-B1 CHOLESTEROL CONJUGATES OF INHIBITORS OF VIRAL FUSION MSD ITALIA SRL (IT) 2019-03-20 — — EP disclosed
US-8629101-B2 Cholesterol derivatives of inhibitors of viral fusion ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2014-01-14 — — US disclosed
US-8629101-B2 Cholesterol derivatives of inhibitors of viral fusion ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2014-01-14 — — US disclosed
US-20130196903-A1 Multimeric Inhibitors of Viral Fusion and Uses Thereof JV BIO SRL (IT) 2013-08-01 — — US disclosed
US-20130196903-A1 Multimeric Inhibitors of Viral Fusion and Uses Thereof JV BIO SRL (IT) 2013-08-01 — — US disclosed
US-20130150563-A1 LIPID-CONJUGATED ANTIBODIES JV BIO SRL (IT) 2013-06-13 — — US disclosed
US-20100305028-A1 CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION MSD ITALIA S.R.L. (IT) 2010-12-02 — — US disclosed
WO-2010089129-A1 INHIBITORS OF VIRAL FUSION AND USES THEREOF CORMUS SRL (IT) 2010-08-12 — — WO disclosed
WO-2009053339-A2 CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150563-A1 LIPID-CONJUGATED ANTIBODIES GPR119, FCGR1A, LIPG POLA1 3845/4885CYP46A1 10/4885PLA2G2A 511/4885
US-20100305028-A1 CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION HDLBP, CETP, NPC1 POLA1 3439/4885CYP46A1 10/4885PLA2G2A 809/4885
US-20130196903-A1 Multimeric Inhibitors of Viral Fusion and Uses Thereof HAVCR2, ZC3HAV1, BST2 POLA1 4407/4885CYP46A1 3039/4885PLA2G2A 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback